Latest Data monitoring committees Stories
In the news release, BrainStorm Announces Positive DSMB Recommendation in Ongoing Phase 2 Trial with NurOwn(TM) in ALS, issued Feb. 3, 2015 by BrainStorm Cell Therapeutics Inc.
No Concerns Identified; DSMB Recommends Trial Continues as Planned HACKENSACK, N.J. and PETACH TIKVAH, Israel, Feb.
Enrollment in Worldwide Trial Continues as Planned REDMOND, Wash., Sept.
Phase III Trial Is Alive And Well; "Hint Of Failure" A Complete Fabrication; No Interim Analysis of Efficacy Done; 55 Patients' Positive Data Independently Collected. BETHESDA, Md., Aug.
BETHESDA, Md., March 7, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers,
- A pivoted catch designed to fall into a notch on a ratchet wheel so as to allow movement in only one direction (e.g. on a windlass or in a clock mechanism), or alternatively to move the wheel in one direction.